Pettorino Roselle MD is categorized under Internal Medicine Doctors in Brownsville, TX and active since 2009.
Pettorino Roselle MD was established in 2009, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Internal Medicine Doctors business, which does work in the B2C market, and is classified as a Internal Medicine Doctors, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Roselle Pettorino at the company’s single location by writing to 864 Central Boulevard # 300, Brownsville, Texas TX 78520 or by phoning (956) 541-6311. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Pettorino Roselle MD |
| Contact Person: | Roselle Pettorino |
| Address: | 864 Central Boulevard # 300, Brownsville, Texas 78520 |
| Phone Number: | (956) 541-6311 |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 2009 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Internal Medicine Doctors |
| SIC Code: | 8011 |
| NAICS Code: | 6211110 |
| Share This Business: |
Pettorino Roselle MD was started in 2009 to provide professional Internal Medicine Doctors under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Roselle Pettorino for inquiries that concern Pettorino Roselle MD by calling the company number (956) 541-6311, as your correspondence is most welcome. Additionally, the physical location of the single location of Pettorino Roselle MD can be found at the coordinates 25.919186,-97.512171 as well as the street address 864 Central Boulevard # 300 in Brownsville, Texas 78520.
For its online presence, you may visit Pettorino Roselle MD’s website at and engage with its social media outlets through on Twitter and on Facebook.